NASDAQ:FOMX Menlo Therapeutics (FOMX) Stock Price, News & Analysis → $21,000 in profits in six weeks? (From InvestorPlace) (Ad) Free FOMX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.99▼$2.9950-Day Range$2.99▼$2.9952-Week Range$1.97▼$4.84VolumeN/AAverage Volume518,350 shsMarket Capitalization$184.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Menlo Therapeutics alerts: Email Address Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story About Menlo Therapeutics Stock (NASDAQ:FOMX)Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.Read More Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story FOMX Stock News HeadlinesApril 30, 2024 | tmcnet.cominsitro Hires AI and Machine Learning Visionary, Emily Fox, Ph.D., as Senior Vice President of AI/MLApril 28, 2024 | msn.comMenlo-Atherton’s Troy Franklin selected by Broncos in fourth round of NFL DraftMay 7, 2024 | InvestorPlace (Ad)The 2024 crypto bull run has already started — don’t get left behindOne of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.April 23, 2024 | markets.businessinsider.comMenlo Micro Appoints Two Leading Defense Industry Experts to its Corporate Advisory BoardApril 18, 2024 | msn.comCamera store in downtown Menlo Park burglarizedApril 17, 2024 | msn.comMenlo Park man arrested on $1.2M human trafficking warrantMarch 26, 2024 | msn.comMenlo Park Mall adding seven new stores, restaurants this spring. Here's what's comingMarch 14, 2024 | msn.comMan arrested on suspicion of firing gun at Menlo Park homeMay 7, 2024 | InvestorPlace (Ad)The 2024 crypto bull run has already started — don’t get left behindOne of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.March 4, 2024 | msn.comMenlo, Micron represent opportunity for Ithaca's manufacturing workforce to growFebruary 22, 2024 | yahoo.comMenlo Park police report increase in home break-ins, suspects targeting ‘affluent neighborhoods’January 29, 2024 | finance.yahoo.comCorcept Appoints Roberto Vieira as President, OncologyDecember 27, 2023 | bizjournals.comMenlo Park builder's remedy project proposal getting biggerDecember 26, 2023 | bizjournals.comCalifornia conditionally approves Menlo Park's housing elementDecember 25, 2023 | msn.comMenlo Park apartment fire kills two people, two dogs Sunday morningDecember 19, 2023 | health.usnews.comIndependent Living Communities Near Menlo Park, CADecember 12, 2023 | msn.comNew citizenM Menlo Park Hotel opens in Silicon Valley, USNovember 28, 2023 | tmcnet.comMenlo Security Strengthens Executive Leadership Team with Chief Marketing Officer and Chief Financial Officer AppointmentsNovember 27, 2023 | msn.comHere’s What You Need to Know About The Stanford Park Hotel, Menlo ParkNovember 16, 2023 | markets.businessinsider.comMenlo Ventures Closes $1.35 Billion to Invest in Companies Leading the AI TransformationNovember 11, 2023 | health.usnews.comDr. Sun Hae ChoiNovember 8, 2023 | msn.comLook: Steve Young, John Paye lead first-year Menlo girls flag football team to 15-1 seasonOctober 29, 2023 | msn.comTwo Alarm Fire at Menlo Park Diner on Saturday NightOctober 28, 2023 | foxnews.comHead of embattled Illinois child services agency to resign at year's endOctober 26, 2023 | finance.yahoo.comCorcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)October 5, 2023 | msn.comGain Therapeutics doses first two subjects in Parkinson’s therapy trialSeptember 22, 2023 | msn.comMenlo Park street shut down due to hazmat situationSee More Headlines Receive FOMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Menlo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2019Today5/06/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & Botanicals Sub-IndustryN/A Current SymbolNASDAQ:FOMX CUSIPN/A CIK1606645 Webwww.foamix.com Phone972-8931-6233FaxN/AEmployees80Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-100.58% Return on Assets-81.39% Debt Debt-to-Equity Ratio0.24 Current Ratio5.72 Quick Ratio5.72 Sales & Book Value Annual Sales$3.60 million Price / Sales51.15 Cash FlowN/A Price / Cash FlowN/A Book Value$1.70 per share Price / Book1.76Miscellaneous Outstanding Shares61,580,000Free FloatN/AMarket Cap$184.12 million OptionableOptionable Beta1.66 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. David T. Domzalski (Age 52)CEO & Director Mr. Ilan Hadar M.B.A. (Age 50)MBA, CFO & Country Mang. Ms. Mutya Harsch (Age 44)Gen. Counsel & Chief Legal Officer Dr. Darrell S. Rigel M.D. (Age 69)MS, Consultant Dr. Iain A. Stuart (Age 46)Chief R&D Officer Key CompetitorsMediWoundNASDAQ:MDWDFitLife BrandsNASDAQ:FTLFChromaDexNASDAQ:CDXCBright GreenNASDAQ:BGXXNatural Alternatives InternationalNASDAQ:NAIIView All Competitors FOMX Stock Analysis - Frequently Asked Questions How were Menlo Therapeutics' earnings last quarter? Menlo Therapeutics Inc. (NASDAQ:FOMX) issued its earnings results on Monday, November, 11th. The specialty pharmaceutical company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.07. What other stocks do shareholders of Menlo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Menlo Therapeutics investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Sangamo Therapeutics (SGMO), Viking Therapeutics (VKTX), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), OPKO Health (OPK) and Pfizer (PFE). This page (NASDAQ:FOMX) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersBiden’s $374B Giveaway Into This SectorDTIAI “wealth window” is closing June 25thParadigm PressThe 2024 crypto bull run has already started — don’t get left behindInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Menlo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
